Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Melanoma"" wg kryterium: Temat


Tytuł :
Identification of metastasis-related genes by genomic and transcriptomic studies in murine melanoma.
Autorzy :
Kadioglu O; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
Saeed MEM; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
Mahmoud N; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany.
Hussein Azawi SS; Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Rincic M; Croatian Institute for Brain Research, School of Medicine University of Zagreb, Zagreb, Croatia.
Liehr T; Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany.
Efferth T; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Feb 15; Vol. 267, pp. 118922. Date of Electronic Publication: 2020 Dec 21.
Typ publikacji :
Journal Article
MeSH Terms :
Melanoma, Experimental/*genetics
Neoplasm Metastasis/*genetics
Animals ; Cell Line, Tumor ; Genome/genetics ; Genomics/methods ; In Situ Hybridization, Fluorescence/methods ; Melanoma/genetics ; Mice ; Mice, Inbred C57BL ; Sequence Analysis, RNA/methods ; Transcriptome/genetics
Czasopismo naukowe
Tytuł :
The dietary flavonoid isoliquiritigenin induced apoptosis and suppressed metastasis in melanoma cells: An in vitro and in vivo study.
Autorzy :
Xiang S; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Zeng H; Clinical Laboratory, University of Chinese Academy of Sciences-Shenzhen Hospital, 518106 Shenzhen, China.
Xia F; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Ji Q; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Xue J; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Ren R; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Que F; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China.
Zhou B; Department of Pharmacy, Seventh Affiliated Hospital of Sun Yat-sen University, 518107 Shenzhen, China. Electronic address: .
Pokaż więcej
Źródło :
Life sciences [Life Sci] 2021 Jan 01; Vol. 264, pp. 118598. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji :
Journal Article
MeSH Terms :
Apoptosis/*drug effects
Chalcones/*administration & dosage
Flavonoids/*administration & dosage
Melanoma/*drug therapy
Skin Neoplasms/*drug therapy
Animals ; Apoptosis/physiology ; Cell Line, Tumor ; Female ; Humans ; Melanoma/pathology ; Melanoma, Experimental/drug therapy ; Melanoma, Experimental/pathology ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Nude ; Skin Neoplasms/pathology ; Xenograft Model Antitumor Assays/methods
Czasopismo naukowe
Tytuł :
Synthesis, characterization and optimization of in vitro properties of NIR-fluorescent cyclic α-MSH peptides for melanoma imaging.
Autorzy :
von Kiedrowski V; Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. .
Hübner R
Kail D
Cheng X
Schirrmacher R
Wängler C
Wängler B
Pokaż więcej
Źródło :
Journal of materials chemistry. B [J Mater Chem B] 2020 Dec 14; Vol. 8 (46), pp. 10602-10608. Date of Electronic Publication: 2020 Nov 02.
Typ publikacji :
Journal Article
MeSH Terms :
Diagnostic Imaging/*methods
Fluorescent Dyes/*chemical synthesis
Melanoma/*diagnostic imaging
Receptor, Melanocortin, Type 1/*analysis
Skin Neoplasms/*diagnostic imaging
Animals ; Fluorescent Dyes/metabolism ; Humans ; Indocyanine Green/analysis ; Indocyanine Green/metabolism ; Melanoma/metabolism ; Melanoma, Experimental ; Mice ; Mice, Nude ; Protein Binding/physiology ; Receptor, Melanocortin, Type 1/metabolism ; Skin Neoplasms/metabolism ; Spectroscopy, Near-Infrared/methods
Czasopismo naukowe
Tytuł :
Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report.
Autorzy :
Misir Krpan A; University Hospital Centre Zagreb, Kispaticeva 12.
Rakusic Z; University Hospital Centre Zagreb, Kispaticeva 12.; University of Zagreb, School of Medicine.
Herceg D; University Hospital Centre Zagreb, Kispaticeva 12.; University of Zagreb, School of Dental Medicine, Zagreb, Croatia.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Dec 11; Vol. 99 (50), pp. e22928.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Melanoma/*drug therapy
Meningeal Neoplasms/*pathology
Aged ; Female ; Humans ; MART-1 Antigen/metabolism ; Melanoma/diagnosis ; Melanoma-Specific Antigens/metabolism ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; S100 Proteins/metabolism ; Seizures/etiology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Oral exposure to BDE-209 modulates metastatic spread of melanoma in C57BL/6 mice inoculated with B16-F10 cells.
Autorzy :
Brito PM; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
Biscaia SMP; Laboratório de Investigações de Polissacarídeos Sulfatados, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
de Souza TL; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
Ramos AB; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
Leão-Buchir J; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
de Almeida Roque A; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
de Lima Bellan D; Laboratório de Investigações de Polissacarídeos Sulfatados, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
da Silva Trindade E; Laboratório de Investigações de Polissacarídeos Sulfatados, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
Filipak Neto F; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil.
de Oliveira Ribeiro CA; Laboratório de Toxicologia Celular, Departamento de Biologia Celular, Universidade Federal Do Paraná, CEP 81.531-980, Curitiba, Brazil. Electronic address: .
Pokaż więcej
Źródło :
Chemosphere [Chemosphere] 2020 Dec; Vol. 260, pp. 127556. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Journal Article
MeSH Terms :
Mice, Inbred C57BL*
Halogenated Diphenyl Ethers/*pharmacology
Melanoma/*pathology
Neoplasm Metastasis/*pathology
Alanine Transaminase/blood ; Animals ; Aspartate Aminotransferases/blood ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Female ; Flame Retardants/pharmacology ; Halogenated Diphenyl Ethers/toxicity ; Heterografts ; Humans ; Liver/drug effects ; Liver/pathology ; Melanoma, Experimental ; Mice
Czasopismo naukowe
Tytuł :
Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Autorzy :
Milman T; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Department of Pathology, Wills Eye Hospital, Philadelphia, PA, 19107, USA. Electronic address: .
Zhang Q; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Biostatistics Consulting Core, Vickie and Jack Farber Vision Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Ang S; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Elder D; Department of Pathology and Laboratory Medicine, Hospital of University of Pennsylvania, Perelman School of Medicine, PA, 19104, USA.
Ida CM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA.
Salomao DR; Department of Laboratory Medicine and Pathology, Mayo Clinic, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA.
Lally SE; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Shields JA; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Hamershock RA; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Biostatistics Consulting Core, Vickie and Jack Farber Vision Research Center, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Sioufi K; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Shields CL; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Ocular Oncology Service, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Eagle RC Jr; Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, 19107, USA; Department of Pathology, Wills Eye Hospital, Philadelphia, PA, 19107, USA.
Pokaż więcej
Źródło :
Human pathology [Hum Pathol] 2020 Sep; Vol. 103, pp. 107-119. Date of Electronic Publication: 2020 Jul 21.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*analysis
Conjunctival Neoplasms/*diagnosis
Cyclin-Dependent Kinase Inhibitor p16/*analysis
Melanoma/*diagnosis
Nevus, Pigmented/*diagnosis
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Diagnosis, Differential ; Female ; Humans ; Immunohistochemistry ; Ki-67 Antigen/analysis ; Male ; Melanoma-Specific Antigens/analysis ; Middle Aged ; SOXE Transcription Factors/analysis ; Young Adult
Czasopismo naukowe
Tytuł :
Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies.
Autorzy :
Frelau A; Department of Oncology, Eugène Marquis Center, Rennes, France.
Palard-Novello X; Department of Nuclear Medicine, Eugène Marquis Center, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.
Jali E; Department of Endocrinology, University Hospital, Brest, France.
Boussemart L; Department of Dermatology, University Hospital, Rennes, France.
Dupuy A; Department of Dermatology, University Hospital, Rennes, France.
James P; Department of Gynecology, University Hospital, Brest, France.
Devillers A; Department of Nuclear Medicine, Eugène Marquis Center, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.
Le Jeune F; Department of Nuclear Medicine, Eugène Marquis Center, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.
Edeline J; Department of Oncology, Eugène Marquis Center, Rennes, France.
Lesimple T; Department of Oncology, Eugène Marquis Center, Rennes, France.
Girard A; Department of Nuclear Medicine, Eugène Marquis Center, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Mar; Vol. 70 (3), pp. 679-687. Date of Electronic Publication: 2020 Sep 03.
Typ publikacji :
Journal Article
MeSH Terms :
Fluorodeoxyglucose F18*
Positron Emission Tomography Computed Tomography*
Hypothyroidism/*diagnosis
Hypothyroidism/*etiology
Melanoma/*complications
Melanoma/*pathology
Thyroid Gland/*diagnostic imaging
Thyroid Gland/*metabolism
Aged ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Kaplan-Meier Estimate ; Male ; Melanoma/drug therapy ; Melanoma/mortality ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Staging ; Prognosis ; ROC Curve
Czasopismo naukowe
Tytuł :
Re-evaluating the ABCD criteria using a consecutive series of melanomas.
Autorzy :
Liu R; University of Pittsburgh School of Medicine, Pennsylvania.
Pugliano-Mauro M; Department of Dermatology, University of Pittsburgh, Pennsylvania.
Patton T; Department of Dermatology, University of Pittsburgh, Pennsylvania.
Wang L; University of Pittsburgh Clinical and Translational Science Institute, Pennsylvania.
Siripong N; University of Pittsburgh Clinical and Translational Science Institute, Pennsylvania.
Ferris LK; Department of Dermatology, University of Pittsburgh, Pennsylvania. Electronic address: .
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Oct; Vol. 83 (4), pp. 1161-1163. Date of Electronic Publication: 2020 Apr 22.
Typ publikacji :
Journal Article
MeSH Terms :
Melanoma/*diagnosis
Skin Neoplasms/*diagnosis
Symptom Assessment/*methods
Aged ; Biopsy ; Consensus ; Dermatologists ; Dermoscopy ; Female ; Humans ; Male ; Melanoma/pathology ; Melanoma, Amelanotic/diagnosis ; Melanoma, Amelanotic/pathology ; Middle Aged ; Neoplasm Invasiveness ; Observer Variation ; Retrospective Studies ; Skin Neoplasms/pathology ; Tumor Burden
SCR Disease Name :
Melanoma, Cutaneous Malignant
Czasopismo naukowe
Tytuł :
A pH-Sensitive Prodrug Nanocarrier Based on Diosgenin for Doxorubicin Delivery to Efficiently Inhibit Tumor Metastasis.
Autorzy :
Wei Z; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.; Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Wang H; Textile Institute, College of Light Industry, Textile and Food Engineering, Sichuan University, Chengdu, People's Republic of China.
Xin G; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Zeng Z; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Li S; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Ming Y; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Zhang X; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Xing Z; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Li L; Department of Dermatology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Li Y; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Zhang B; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.; Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.
Zhang J; Tianjin University of Traditional Chinese Medicine, Tianjin, People's Republic of China.
Niu H; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.; College of Mathematics, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Huang W; Laboratory of Ethnopharmacology, West China Medical School, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 Sep 04; Vol. 15, pp. 6545-6560. Date of Electronic Publication: 2020 Sep 04 (Print Publication: 2020).
Typ publikacji :
Journal Article
MeSH Terms :
Doxorubicin/*administration & dosage
Drug Carriers/*chemistry
Melanoma/*drug therapy
Nanoparticles/*chemistry
Prodrugs/*administration & dosage
Skin Neoplasms/*drug therapy
Animals ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/pharmacokinetics ; Antibiotics, Antineoplastic/pharmacology ; Apoptosis/drug effects ; Cell Line, Tumor ; Diosgenin/chemistry ; Doxorubicin/pharmacokinetics ; Doxorubicin/pharmacology ; Drug Carriers/administration & dosage ; Drug Delivery Systems/methods ; Humans ; Hydrogen-Ion Concentration ; Male ; Melanoma/pathology ; Melanoma/secondary ; Melanoma, Experimental/drug therapy ; Melanoma, Experimental/pathology ; Mice, Inbred BALB C ; Nanoparticles/administration & dosage ; Prodrugs/pharmacology ; Skin Neoplasms/pathology ; Skin Neoplasms/secondary ; Tissue Distribution
SCR Disease Name :
Melanoma, Cutaneous Malignant
Czasopismo naukowe
Tytuł :
[A case of meningeal melanomatosis diagnosed by immunostaining of cerebrospinal fluid].
Autorzy :
Tamura Y; Department of Neurology, Nagaoka Red Cross Hospital.
Umeda Y; Department of Neurology, Nagaoka Red Cross Hospital.
Umeda M; Department of Neurology, Nagaoka Red Cross Hospital.
Oyake M; Department of Neurology, Nagaoka Red Cross Hospital.
Usuda H; Department of Pathology, Nagaoka Red Cross Hospital.
Fujita N; Department of Neurology, Nagaoka Red Cross Hospital.
Pokaż więcej
Źródło :
Rinsho shinkeigaku = Clinical neurology [Rinsho Shinkeigaku] 2020 Aug 07; Vol. 60 (8), pp. 565-568. Date of Electronic Publication: 2020 Jul 07.
Typ publikacji :
Journal Article
MeSH Terms :
Cerebrospinal Fluid*
Biomarkers, Tumor/*cerebrospinal fluid
Cytodiagnosis/*methods
Melanoma/*cerebrospinal fluid
Melanoma/*diagnosis
Meningeal Carcinomatosis/*cerebrospinal fluid
Meningeal Carcinomatosis/*diagnosis
Meningeal Neoplasms/*cerebrospinal fluid
Meningeal Neoplasms/*diagnosis
Staining and Labeling/*methods
Aged ; Female ; Humans ; Melanoma-Specific Antigens/cerebrospinal fluid ; Neoplasms, Unknown Primary ; S100 Proteins/cerebrospinal fluid
Czasopismo naukowe
Tytuł :
Treatment Contraindications Based on Comorbidity Status in Patients With Melanoma in the United States.
Autorzy :
Boczar D; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Bagaria SP; Department of Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Spaulding AC; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL, U.S.A.
Huayllani MT; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Avila FR; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Guliyeva G; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Lu X; Division of Plastic and Reconstructive Surgery, Yale School of Medicine, New Haven, CT, U.S.A.
Rinker BD; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.
Forte AJ; Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, U.S.A.; .
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Apr; Vol. 41 (4), pp. 2067-2070.
Typ publikacji :
Journal Article
MeSH Terms :
Contraindications*
Melanoma/*epidemiology
Melanoma/*therapy
Skin Neoplasms/*epidemiology
Skin Neoplasms/*therapy
Adult ; Aged ; Aged, 80 and over ; Comorbidity ; Databases, Factual ; Female ; Healthcare Disparities/statistics & numerical data ; Humans ; Male ; Melanoma/pathology ; Middle Aged ; Practice Patterns, Physicians'/statistics & numerical data ; Skin Neoplasms/pathology ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
Autorzy :
Ahmed FS; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA. .
Dercle L; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA.
Goldmacher GV; Merck & Co. Pharmaceutical, Warrington, PA, USA.
Yang H; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA.
Connors D; Foundation for the National Institute of Health, Bethesda, MD, USA.
Tang Y; CCS Associates, San Jose, CA, USA.
Karovic S; Inova Schar Cancer Institute, Washington, DC, USA.
Zhao B; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA.
Carvajal RD; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA.
Robert C; Gustave Roussy Cancer Campus, Paris, France.
Maitland ML; Inova Schar Cancer Institute, Washington, DC, USA.
Oxnard GR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Schwartz LH; Columbia University Irving Medical Center, 622 W 168th Street, PHB-1, New York, NY, 10032, USA.
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2021 Apr; Vol. 31 (4), pp. 1853-1862. Date of Electronic Publication: 2020 Sep 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*/therapeutic use
Melanoma*/diagnostic imaging
Melanoma*/drug therapy
Humans ; Immunotherapy ; Response Evaluation Criteria in Solid Tumors
Czasopismo naukowe
Tytuł :
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Autorzy :
Punt S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Malu S; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Immunitas Therapeutics, Cambridge, MA, USA.
McKenzie JA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Eisai Inc., Woodcliff Lake, NJ, USA.
Manrique SZ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Doorduijn EM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Mbofung RM; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Merck Research Laboratories, Palo Alto, CA, USA.
Williams L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; KSQ Therapeutics Inc., Cambridge, MA, USA.
Silverman DA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Ashkin EL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Dominguez AL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Wang Z; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Nature Cell Biology, Springer Nature, Shanghai City, China.
Chen JQ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; EMD Serono, Rockland, MA, USA.
Maiti SN; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Tieu TN; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; C4 Therapeutics, Watertown, MA, USA.
Liu C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Xu C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; University of Houston, Houston, TX, USA.
Forget MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Haymaker C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Khalili JS; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; SystImmune Inc., Redmond, WA, USA.
Satani N; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Muller F; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Cooper LJN; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; ZIOPHARM Oncology Inc., Boston, MA, USA.
Overwijk WW; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Nektar Therapeutics, San Francisco, CA, USA.
Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Heffernan TP; Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Peng W; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; University of Houston, Houston, TX, USA.
Roszik J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. .; Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. .; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Apr; Vol. 70 (4), pp. 1101-1113. Date of Electronic Publication: 2020 Oct 29.
Typ publikacji :
Journal Article
MeSH Terms :
Aurora Kinase A/*metabolism
Aurora Kinase B/*metabolism
Drug Resistance, Neoplasm/*immunology
Immunotherapy/*methods
Lymphocytes, Tumor-Infiltrating/*immunology
Melanoma/*immunology
T-Lymphocytes, Cytotoxic/*transplantation
Animals ; Apoptosis ; Aurora Kinase A/antagonists & inhibitors ; Aurora Kinase A/genetics ; Aurora Kinase B/antagonists & inhibitors ; Aurora Kinase B/genetics ; Cell Proliferation ; Female ; Humans ; Melanoma/genetics ; Melanoma/metabolism ; Melanoma/therapy ; Mice ; Prognosis ; Survival Rate ; T-Lymphocytes, Cytotoxic/immunology ; Tumor Cells, Cultured ; Tumor Microenvironment/immunology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data .
Autorzy :
Di Filippo Y; Dermatology Department, University Hospital of Nice, and INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France.
Dalle S; Hospices Civils De Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France.
Mortier L; Dermatology Department, University of Lille, Lille, France.
Dereure O; Dermatology Department, University Hospital of Montpellier, Montpellier, France.
Dalac S; Dermatology Department, University Hospital of Dijon, Dijon, France.
Dutriaux C; Dermatology Department, Bordeaux Hospital, Bordeaux, France.
Leccia MT; Dermatology Department, University of Grenoble, Grenoble, France.
Legoupil D; Dermatology Department, CHU Brest, Brest, France.
Saiag P; AP-HP, Dermatology, Ambroise Paré Hospital, & EA4340, UVSQ University and Paris-Saclay University, Boulogne-Billancourt, France.
Brunet-Possenti F; AP-HP, Dermatology, Bichat Hospital, Paris, France.
Arnnault JP; Dermatology Department, CHU Amiens-Picardie, Amiens, France.
Maubec E; Dermatology Department, Hôpital Avicenne, Bobigny, France.
Granel-Brocard F; Dermatology Department, CHRU Nancy, Vandoeuvre-Les-Nancy, France.
De Quatrebarbes J; Dermatology Department, CHR Annecy Genevois, Annecy, France.
Aubin F; Dermatology Department, CHU de Besançon, Besançon, France.
Lesimple T; Dermatology Department, CLCC Rennes Eugène Marquis, Rennes, France.
Beylot-Barry M; Dermatology Department, CHU Bordeaux, Bordeaux, France.
Stoebner PE; Dermatology Department, CHU de Nimes, Nimes, France.
Dupuy A; Dermatology Department, Rennes Hospital, Rennes, France.
Stephan A; Dermatology Department, Caen, France.
Grob JJ; Dermatology Department, Hopital de la Timone, Aix-Marseille University, Marseilles, France.
Lefevre W; AP-HP Oncodermatology Department, Saint-Louis Hospital, INSERM U976, Université de Paris, Paris, France.
Oriano B; Clinical Epidemiology Center, AP-HP, Hôtel-Dieu, Paris, France.
Allayous C; AP-HP Oncodermatology Department, Saint-Louis Hospital, INSERM U976, Université de Paris, Paris, France.
Lebbé C; AP-HP Oncodermatology Department, Saint-Louis Hospital, INSERM U976, Université de Paris, Paris, France.
Montaudié H; Dermatology Department, University Hospital of Nice, and INSERM U1065, Centre Méditerranéen de Médecine Moléculaire, Université Côte d'Azur, Nice, France. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Apr; Vol. 32 (4), pp. 542-551. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Melanoma*/drug therapy
Melanoma*/epidemiology
Adult ; Aged ; Body Mass Index ; Humans ; Male ; Progression-Free Survival ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Autorzy :
Winter J; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Lenders MM; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Gassenmaier M; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Forschner A; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Leiter U; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Weide B; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Purde MT; Department of Dermatology, Venereology and Allergology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, CH-9007, St. Gallen, Switzerland.
Flatz L; Department of Dermatology, Venereology and Allergology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, CH-9007, St. Gallen, Switzerland.
Cozzio A; Department of Dermatology, Venereology and Allergology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, CH-9007, St. Gallen, Switzerland.
Röcken M; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Garbe C; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Eigentler TK; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Wagner NB; Department of Dermatology, University Hospital Tübingen, Tübingen, Germany. .; Department of Dermatology, Venereology and Allergology, Cantonal Hospital St. Gallen, Rorschacherstrasse 95, CH-9007, St. Gallen, Switzerland. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Apr; Vol. 70 (4), pp. 1089-1099. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*metabolism
Gene Expression Regulation, Enzymologic/*drug effects
Gene Expression Regulation, Neoplastic/*drug effects
Melanoma/*pathology
gamma-Glutamyltransferase/*metabolism
Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Ipilimumab/administration & dosage ; Male ; Melanoma/drug therapy ; Melanoma/enzymology ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Sustained IL-2R signaling of limited duration by high-dose mIL-2/mCD25 fusion protein amplifies tumor-reactive CD8 T cells to enhance antitumor immunity.
Autorzy :
Hernandez R; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
Toomer KH; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
Põder J; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
Santos Savio A; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
Hsiung S; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA.
Malek TR; Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, FL, 33136, USA. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Apr; Vol. 70 (4), pp. 909-921. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :
Journal Article
MeSH Terms :
CD8-Positive T-Lymphocytes/*immunology
Interleukin-2/*administration & dosage
Interleukin-2 Receptor alpha Subunit/*administration & dosage
Killer Cells, Natural/*immunology
Melanoma, Experimental/*immunology
Recombinant Fusion Proteins/*administration & dosage
T-Lymphocytes, Regulatory/*immunology
Animals ; Antigens, Neoplasm ; Female ; Humans ; Interleukin-2/immunology ; Interleukin-2 Receptor alpha Subunit/immunology ; Male ; Melanoma, Experimental/metabolism ; Melanoma, Experimental/pathology ; Melanoma, Experimental/therapy ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Recombinant Fusion Proteins/immunology ; Signal Transduction ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Autorzy :
Kiniwa Y; Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.
Okuyama R; Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Mar 03; Vol. 51 (3), pp. 315-320.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Molecular Targeted Therapy*
Melanoma/*drug therapy
Melanoma/*genetics
Mutation/*genetics
Proto-Oncogene Proteins B-raf/*genetics
Skin Neoplasms/*drug therapy
Skin Neoplasms/*genetics
Brain Neoplasms/drug therapy ; Humans ; Melanoma/pathology ; Neoplasm Metastasis ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Effect of Metformin in Combination With Trametinib and Paclitaxel on Cell Survival and Metastasis in Melanoma Cells.
Autorzy :
Lee Y; Department of Histology, Jeju National University School of Medicine, Jeju, Republic of Korea .
Park D; Department of Histology, Jeju National University School of Medicine, Jeju, Republic of Korea.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Mar; Vol. 41 (3), pp. 1387-1399.
Typ publikacji :
Journal Article
MeSH Terms :
Melanoma/*pathology
Metformin/*pharmacology
Paclitaxel/*pharmacology
Pyridones/*pharmacology
Pyrimidinones/*pharmacology
Skin Neoplasms/*pathology
Antineoplastic Agents/pharmacology ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Cell Survival/drug effects ; Drug Synergism ; Epithelial-Mesenchymal Transition/drug effects ; Humans ; Melanoma/genetics ; Melanoma/metabolism ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Signal Transduction/drug effects ; Skin Neoplasms/genetics ; Skin Neoplasms/metabolism
Czasopismo naukowe
Tytuł :
Adjuvant immunotherapy for melanoma.
Autorzy :
Thomas D; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
Bello DM; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.
Pokaż więcej
Źródło :
Journal of surgical oncology [J Surg Oncol] 2021 Mar; Vol. 123 (3), pp. 789-797.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Immunotherapy/*methods
Melanoma/*therapy
Skin Neoplasms/*therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Trials, Phase III as Topic ; Combined Modality Therapy ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Melanoma/immunology ; Melanoma/pathology ; Melanoma/surgery ; Neoplasm Staging ; Randomized Controlled Trials as Topic ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Skin Neoplasms/surgery
Czasopismo naukowe
Tytuł :
Cobimetinib plus atezolizumab in BRAF wild-type melanoma: primary results from the randomized phase III IMspire170 study.
Autorzy :
Gogas H; First Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. Electronic address: .
Dréno B; Dermatology Department, CHU Nantes, CIC 1413, CRCINA, University Nantes, Nantes, France.
Larkin J; Royal Marsden NHS Foundation Trust, London, United Kingdom.
Demidov L; N.N. Blokhin Russian Cancer Research Center, Ministry of Health, Moscow, Russia.
Stroyakovskiy D; Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow Oblast, Russia.
Eroglu Z; Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA.
Francesco Ferrucci P; European Institute of Oncology - IRCCS, Milan, Italy.
Pigozzo J; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Mackiewicz J; Department of Medical and Experimental Oncology, Poznan University of Medical Sciences, and Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Center, Poznan, Poland.
Rooney I; Genentech, Inc., South San Francisco, USA.
Voulgari A; Roche Products Ltd, Welwyn Garden City, UK.
Troutman S; Genentech, Inc., South San Francisco, USA.
Pitcher B; Hoffmann-La Roche Ltd., Mississauga, Canada.
Guo Y; Genentech, Inc., South San Francisco, USA.
Yan Y; Genentech, Inc., South San Francisco, USA.
Castro M; Genentech, Inc., South San Francisco, USA.
Mulla S; Hoffmann-La Roche Ltd., Mississauga, Canada.
Flaherty K; Massachusetts General Hospital Cancer Center, Boston, USA.
Arance A; Department of Medical Oncology and IDIBAPS, Hospital Clínic Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Mar; Vol. 32 (3), pp. 384-394. Date of Electronic Publication: 2020 Dec 10.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Melanoma*/drug therapy
Melanoma*/genetics
Proto-Oncogene Proteins B-raf*/genetics
Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azetidines ; Humans ; Piperidines
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies